Eszopiclone After 65: 4 Trial Checks

Bring the study’s dose, outcome and follow-up to a prescription review. These four checks help frame that conversation.

Diary benefit

The trial assigned 388 adults aged 65–85 to nightly 2 mg eszopiclone or placebo for twelve weeks. MMSE cognition scores were ≥28; stable illnesses were allowed. Sepracor funded it; four authors worked for the company during the study.¹

Registered mean sleep-diary increases were 63.24 versus 33.18 minutes, averaged across treatment assessments, P<.0001. Each arm analyzed 191 people, using carried-forward observations for missing assessments. This is not a week-twelve result from all 388 participants.²

Safety limits

Reported unpleasant taste occurred in 12.4% versus 1.5%. Blinding success was untested. No driving test was performed. The four-week stopping analysis covered selected completers; no worsening below pretreatment sleep does not establish safe abrupt stopping.¹

The 2023 AGS Beers Criteria recommend avoiding Z-drugs, including eszopiclone, in older adults, citing delirium, falls, fractures and motor-vehicle crashes alongside limited sleep benefits. This is a prescribing recommendation, rather than an absolute contraindication. Ask how your fall history, cognition and other medicines affect the decision.³

Today’s label

The current US Lunesta label recommends starting at 1 mg and limits older or debilitated patients to 2 mg. Allow 7–8 hours before planned awakening. At 2 mg, next-day impairment can occur despite feeling better. Alcohol and other sedating medicines increase risk; older adults face greater fall risk.⁴

After sleepwalking, sleep-driving or another activity while incompletely awake, stop Lunesta and contact the prescriber immediately. Such an episode contraindicates taking it again. For an ordinary planned change, ask for instructions: the label warns of withdrawal after rapid reduction or abrupt discontinuation.⁴

Treatment plan

The 2026 AASM⁵ guideline conditionally favors starting CBT-I with medication over medication alone, but conditionally advises against routinely choosing the combination over CBT-I alone. Both recommendations have low-certainty evidence. It addresses concurrent treatment initiation, without supplying a withdrawal schedule for someone already taking a sleeping pill.⁵

Agree on a review date. Record grogginess, falls, sleep timing and medicines. Bring those notes to the appointment; follow your prescribed dose.

Did I Do That in My Sleep? includes “Medicines Belong in Shared Decisions,” covering expected benefits, adverse effects, interactions and review plans. Use those prompts to prepare for the appointment.